3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
19
Papillomavirus Vaccines
16
Vaccines
10
Data Collection
9
Blood Specimen Collection
5
Vaccines, Synthetic
4
artesunic acid
3
artemisinin
3
Engerix-B
3
halofantrine
2
epigallocatechin gallate
2
artenimol
2
Hepatitis A Vaccines
2
GX-188 vaccine
2
Colposcopy
2
ranpirnase
1
fludarabine
1
Viusid
1
Vitamin B 12
1
VP-102
1
VGX-3100
1
Therapies, Investigational
1
Sodium Chloride
1
Pentetic Acid
1
Observation
1
Methods
1
Measles-Mumps-Rubella Vaccine
1
Interleukin-2
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Papillomavirus Infections
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts